{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:36:26Z","timestamp":1793097386385,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2022-03342"],"award-info":[{"award-number":["RGPIN-2022-03342"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100397","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:26:36Z","timestamp":1788305196000},"page":"100397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Idelalisib 8-oxidation as an enzyme-selective catalytic marker of human aldehyde oxidase in HepG2 cells: Application to the investigation of enzyme inactivation"],"prefix":"10.1016","volume":"54","author":[{"given":"Nicholas Kai Ming","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian Wen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres Kai Zhi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hao","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-1903","authenticated-orcid":false,"given":"Vijaya Saradhi","family":"Mettu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-5223","authenticated-orcid":false,"given":"Aik Jiang","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmd.2026.100397_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/03602532.2022.2144879","article-title":"Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development","volume":"54","author":"Gajula","year":"2022","journal-title":"Drug Metab Rev"},{"issue":"11","key":"10.1016\/j.dmd.2026.100397_bib2","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1021\/acs.molpharmaceut.0c00559","article-title":"Characterization of differential tissue abundance of major non-CYP enzymes in human","volume":"17","author":"Basit","year":"2020","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.dmd.2026.100397_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.70058","article-title":"UHPLC-MS\/MS quantification of human cytosolic aldehyde oxidase: heat-assisted in-solution protein denaturation and digestion","volume":"40","author":"Chen","year":"2026","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"10.1016\/j.dmd.2026.100397_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00204-016-1683-1","article-title":"Structure and function of mammalian aldehyde oxidases","volume":"90","author":"Terao","year":"2016","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0090-9556(25)06527-4","article-title":"Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver","volume":"23","author":"Clarke","year":"1995","journal-title":"Drug Metab Dispos"},{"issue":"47","key":"10.1016\/j.dmd.2026.100397_bib6","doi-asserted-by":"crossref","first-page":"33366","DOI":"10.1074\/jbc.274.47.33366","article-title":"Metabolism of retinaldehyde and other aldehydes in soluble extracts of human liver and kidney","volume":"274","author":"Ambroziak","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.toxlet.2005.08.004","article-title":"Neo-nicotinoid metabolic activation and inactivation established with coupled nicotinic receptor-CYP3A4 and -aldehyde oxidase systems","volume":"161","author":"Honda","year":"2006","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.dmd.2026.100397_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-0716-1554-6_10","article-title":"Enzyme kinetics, pharmacokinetics, and inhibition of aldehyde oxidase","volume":"2342","author":"Paragas","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100397_bib9","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/dmd.110.033555","article-title":"In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase","volume":"38","author":"Zientek","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.111.042861","article-title":"Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes","volume":"40","author":"Hutzler","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/dmd.118.082099","article-title":"Evaluation of carbazeran 4-oxidation and O6-benzylguanine 8-oxidation as catalytic markers of human aldehyde oxidase: Impact of cytosolic contamination of liver microsomes","volume":"47","author":"Xie","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib12","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1124\/dmd.114.060368","article-title":"Aldehyde oxidase activity in fresh human skin","volume":"42","author":"Manevski","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100397_bib13","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1021\/acsomega.7b01054","article-title":"ecoAO: A simple system for the study of human aldehyde oxidases role in drug metabolism","volume":"2","author":"Paragas","year":"2017","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.dmd.2026.100397_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1124\/dmd.118.085787","article-title":"Time course of aldehyde oxidase and why it is nonlinear","volume":"47","author":"Abbasi","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/dmd.32.1.89","article-title":"Potent inhibition of human liver aldehyde oxidase by raloxifene","volume":"32","author":"Obach","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100397_bib16","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1124\/dmd.111.041806","article-title":"Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions","volume":"39","author":"Barr","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100397_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bcp.2018.04.017","article-title":"Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions","volume":"154","author":"Takaoka","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100397_bib18","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1124\/dmd.123.001379","article-title":"Dissecting parameters contributing to the underprediction of aldehyde oxidase-mediated metabolic clearance of drugs","volume":"51","author":"Subash","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/jpet.119.259267","article-title":"In vitro and in silico analyses of the inhibition of human aldehyde oxidase by bazedoxifene, lasofoxifene, and structural analogues","volume":"371","author":"Chen","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1124\/jpet.120.265249","article-title":"In vitro inhibition of human aldehyde oxidase activity by clinically relevant concentrations of gefitinib and erlotinib: Comparison with select metabolites, molecular docking analysis, and impact on hepatic metabolism of zaleplon and methotrexate","volume":"374","author":"Tan","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100397_bib21","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/acs.molpharmaceut.3c01147","article-title":"Ontogeny of human liver aldehyde oxidase: developmental changes and implications for drug metabolism","volume":"21","author":"Subash","year":"2024","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/psp4.13255","article-title":"Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates","volume":"14","author":"Izat","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100397_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.118.080523","article-title":"Abundance of phase 1 and 2 drug-metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study","volume":"46","author":"Prasad","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100397_bib24","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.xphs.2021.03.020","article-title":"Ultrasensitive quantification of drug-metabolizing enzymes and transporters in small sample volume by microflow LC-MS\/MS","volume":"110","author":"Ahire","year":"2021","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100397_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100051","article-title":"Improved clearance predictions for aldehyde oxidase substrates using a novel triculture human hepatocyte model","volume":"53","author":"Byer-Alcorace","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2.2.183","article-title":"Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies","volume":"2","author":"Castell","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2026.100397_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2025.101478","article-title":"In vitro liver models for toxicological research","volume":"62","author":"Fukunaga","year":"2025","journal-title":"Drug Metab Pharmacokinet"},{"issue":"18","key":"10.1016\/j.dmd.2026.100397_bib28","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.3390\/molecules30183729","article-title":"Recent advances in one-pot multicomponent reactions for the synthesis of substituted quinazolin-4(3H)-ones","volume":"30","author":"Malinowski","year":"2025","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.dmd.2026.100397_bib29","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.dmd.2026.100397_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105239","article-title":"Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia","volume":"221","author":"Stozek-Tutro","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100397_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/acs.chemrestox.8b00023","article-title":"Identification of novel pathways in idelalisib metabolism and bioactivation","volume":"31","author":"Zhu","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmd.2026.100397_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpba.2018.09.027","article-title":"Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies comparison","volume":"162","author":"Chen","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40262-015-0304-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of idelalisib","volume":"55","author":"Ramanathan","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"10.1016\/j.dmd.2026.100397_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313135","article-title":"The curious case of the HepG2 cell line: 40 years of expertise","volume":"22","author":"Arzumanian","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100397_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1055\/s-2007-992129","article-title":"Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes","volume":"39","author":"Sigruener","year":"2007","journal-title":"Horm Metab Res"},{"issue":"9","key":"10.1016\/j.dmd.2026.100397_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100123","article-title":"Visualization of CYP3A4 expression at both mRNA and protein levels simultaneously at single cell resolution in various conditions using RNAscope combined with immunofluorescence","volume":"53","author":"Jin","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100397_bib37","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/hep.1840180535","article-title":"Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes","volume":"18","author":"Schuetz","year":"1993","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.dmd.2026.100397_bib38","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1007\/s00204-025-04139-4","article-title":"Nutrient environment improves drug metabolic activity in human iPSC-derived hepatocytes and HepG2","volume":"99","author":"Pozo Garcia","year":"2025","journal-title":"Arch Toxicol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100397_bib39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12272-014-0502-6","article-title":"HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics","volume":"38","author":"Choi","year":"2015","journal-title":"Arch Pharm Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100397_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/00498250310001657568","article-title":"Phase I and II enzyme characterization of two sources of HepG2 cell lines","volume":"34","author":"Hewitt","year":"2004","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol Toxicol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100397_bib42","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/cells11101677","article-title":"Generation of HepG2 cells with high expression of multiple drug-metabolizing enzymes for drug discovery research using a PITCh system","volume":"11","author":"Negoro","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2025.100097","article-title":"Mechanism-based inactivation of human aldehyde oxidase by erlotinib: Mechanistic insights from structural analogs and molecular docking","volume":"108","author":"Kweh","year":"2026","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2026.100397_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.phrs.2017.03.007","article-title":"Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid","volume":"120","author":"Seow","year":"2017","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100397_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100229","article-title":"Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from kcat measurements in matched liver and intestinal samples","volume":"54","author":"Al-Majdoub","year":"2026","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100397_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jprot.2016.01.016","article-title":"In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes","volume":"136","author":"Wisniewski","year":"2016","journal-title":"J Proteomics"},{"issue":"3","key":"10.1016\/j.dmd.2026.100397_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"issue":"7","key":"10.1016\/j.dmd.2026.100397_bib48","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100397_bib49","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/dmd.120.000017","article-title":"Application of azamulin to determine the contribution of CYP3A4\/5 to drug metabolic clearance using human hepatocytes","volume":"48","author":"Chanteux","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/dmd.114.058750","article-title":"Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes","volume":"43","author":"Zientek","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/00498254.2018.1434913","article-title":"Methoxsalen as an in vitro phenotyping tool in comparison with 1-aminobenzotriazole","volume":"49","author":"Palacharla","year":"2019","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(25)12826-7","article-title":"Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes","volume":"277","author":"Bourri\u00e9","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100397_bib53","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/dmd.113.056374","article-title":"Why do most human liver cytosol preparations lack xanthine oxidase activity?","volume":"42","author":"Barr","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100397_bib54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/00498254.2013.819594","article-title":"Identification of a suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions","volume":"44","author":"Nirogi","year":"2014","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmd.2026.100397_bib55","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.xphs.2018.11.007","article-title":"Evaluation of cytochrome P450 selectivity for hydralazine as an aldehyde oxidase inhibitor for reaction phenotyping","volume":"108","author":"Yang","year":"2019","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100397_bib56","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.123.001257","article-title":"Mechanistic investigation of the time-dependent aldehyde oxidase inhibitor hydralazine","volume":"51","author":"Barnes","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.abb.2006.12.032","article-title":"Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues","volume":"460","author":"Kundu","year":"2007","journal-title":"Arch Biochem Biophys"},{"issue":"9","key":"10.1016\/j.dmd.2026.100397_bib58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/dmd.121.000549","article-title":"The inactivation of human aldehyde oxidase 1 by hydrogen peroxide and superoxide","volume":"49","author":"Garrido","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"10.1016\/j.dmd.2026.100397_bib59","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/1873-3468.14669","article-title":"Mechanistic insights into the ROS-mediated inactivation of human aldehyde oxidase","volume":"597","author":"Esmaeeli","year":"2023","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/j.dmd.2026.100397_bib60","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1021\/mp4003046","article-title":"Absolute quantification of aldehyde oxidase protein in human liver using liquid chromatography-tandem mass spectrometry","volume":"10","author":"Barr","year":"2013","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/dmd.112.048546","article-title":"Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase","volume":"41","author":"Barr","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100397_bib62","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1124\/dmd.123.001436","article-title":"Challenges and opportunities for in vitro-in vivo extrapolation of aldehyde oxidase-mediated clearance: Toward a roadmap for quantitative translation","volume":"51","author":"Izat","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100397_bib63","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1021\/acsinfecdis.9b00012","article-title":"Quantifying the interactions between biomolecules: guidelines for assay design and data analysis","volume":"5","author":"Tonge","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"1","key":"10.1016\/j.dmd.2026.100397_bib64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2133\/dmpk.25.16","article-title":"System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes","volume":"25","author":"Parkinson","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmd.2026.100397_bib65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/17425255.4.5.591","article-title":"Studying cytochrome P450 kinetics in drug metabolism","volume":"4","author":"Kramer","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100397_bib66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1208\/s12248-014-9691-7","article-title":"Addressing the challenges of low clearance in drug research","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.dmd.2026.100397_bib67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol Sin"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:20:04Z","timestamp":1793096404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006665"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100397","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idelalisib 8-oxidation as an enzyme-selective catalytic marker of human aldehyde oxidase in HepG2 cells: Application to the investigation of enzyme inactivation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100397"}}